Alpha 2.0
Login Register
» Authors » Calogero Camma

Calogero Camma

Explore the profile of Calogero Camma including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 193
Citations 5047
Followers 0
Related Specialties
Gastroenterology
Oncology
General Medicine
Top 10 Co-Authors
Antonio Craxi
Salvatore Petta
Vito Di Marco
Giuseppe Cabibbo
Marco Enea
Ciro Celsa
Anna Licata
Daniela Cabibi
Vincenza Calvaruso
Marcello Maida
Published In
J Hepatol
Hepatology
Liver Int
Dig Liver Dis
Clin Gastroenterol Hepatol
Affiliations
Soon will be listed here.
Recent Articles
1.
Does the hepatologist still need to rely on aminotransferases in clinical practice? A reappraisal of the role of a classic biomarker in the diagnosis and clinical management of chronic liver diseases
Burra P, Camma C, Invernizzi P, Marra F, Pompili M
Ann Hepatol . 2025 Mar; :101900. PMID: 40089150
Aminotransferases, particularly alanine aminotransferase (ALT), are commonly used in the detection, diagnosis, and management of chronic liver diseases. ALT, a sensitive and cost-effective marker of liver injury, remains pivotal in...
2.
A Markov Model Unveiling the Impact of Resmetirom on the Natural History of MASLD Patients: A Sistematic Review and Meta-Analysis
Pennisi G, Di Maria G, Enea M, Vaccaro M, Celsa C, Antonucci M, et al.
Liver Int . 2025 Mar; 45(4):e70056. PMID: 40066918
Background And Aim: The MAESTRO-NASH phase 3 trial reported that a 52-week treatment of Resmetirom is effective in improving fibrosis and metabolic dysfunction-associated steatohepatitis (MASH) in patients with MASH and...
3.
Glucagon-like peptide-1 receptor agonist use is associated with a lower risk of major adverse liver-related outcomes: a meta-analysis of observational cohort studies
Celsa C, Pennisi G, Tulone A, Ciancimino G, Vaccaro M, Infantino G, et al.
Gut . 2025 Feb; PMID: 40015951
Background: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have shown promising effects on liver histology in phase 2 trials enrolling patients with metabolic dysfunction-associated steatotic liver disease. However, the impact of GLP-1RAs...
4.
Noninvasive Assessment of portal Hypertension in Patients With Primary Biliary Cholangitis is Affected by Severity of Cholestasis
Calvaruso V, Celsa C, Cristoferi L, Scaravaglio M, Smith R, Kaur S, et al.
Clin Gastroenterol Hepatol . 2024 Dec; PMID: 39674236
Background & Aims: Noninvasive tests (NITs) for ruling-out clinical significant portal hypertension (CSPH) and high-risk varices (HRVs) in patients with primary biliary cholangitis (PBC) and compensated advanced chronic liver disease...
5.
Early Hepatic Decompensation Identifies Patients with Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab or Sorafenib at Highest Risk of Death
Cabibbo G, Celsa C, Battaglia S, Enea M, Di Maria G, Grova A, et al.
Clin Cancer Res . 2024 Nov; 31(3):543-550. PMID: 39576248
Purpose: The prognosis of patients with unresectable hepatocellular carcinoma (HCC) and compensated cirrhosis is influenced by cancer progression. Data on the incidence and the prognostic role of clinical hepatic decompensation...
6.
The Application of Large Language Models in Gastroenterology: A Review of the Literature
Maida M, Celsa C, Lau L, Ligresti D, Baraldo S, Ramai D, et al.
Cancers (Basel) . 2024 Oct; 16(19). PMID: 39409948
Large language models (LLMs) are transforming the medical landscape by enhancing access to information, diagnostics, treatment customization, and medical education, especially in areas like Gastroenterology. LLMs utilize extensive medical data...
7.
What is the benefit of prophylaxis to prevent HBV reactivation in HBsAg-negative anti-HBc-positive patients? Meta-analysis and decision curve analysis
Celsa C, Rizzo G, Di Maria G, Enea M, Vaccaro M, Rancatore G, et al.
Liver Int . 2024 Aug; 44(11):2890-2903. PMID: 39206573
Background And Aims: Patients with overt or occult hepatitis B virus (HBV) infection receiving immunosuppressive treatments have a wide risk of HBV reactivation (HBVr). We performed meta-analysis with decision curve...
8.
Clinical outcomes of MAFLD versus NAFLD: A meta-analysis of observational studies
Pennisi G, Infantino G, Celsa C, Di Maria G, Enea M, Vaccaro M, et al.
Liver Int . 2024 Aug; 44(11):2939-2949. PMID: 39157862
Importance: The recent change in terminology from nonalcoholic fatty liver disease (NAFLD) to metabolic dysfunction-associated fatty liver disease (MAFLD) and metabolic dysfunction-associated steatotic liver disease (MASLD) highlights the link between...
9.
Correlation between endoscopic ultrasound features and exocrine pancreatic function in chronic pancreatitis
Stornello C, Deli C, DellAnna G, Lauri G, Ponz de Leon Pisani R, Tacelli M, et al.
Pancreatology . 2024 Aug; 24(6):834-839. PMID: 39138091
Background: Endoscopic ultrasound (EUS) is the most sensitive method for diagnosing chronic pancreatitis (CP) in its early stages, and Rosemont Classification (RC) is used for its evaluation. Data on the...
10.
Hepatic decompensation is the major driver of mortality in patients with HCC treated with atezolizumab plus bevacizumab: The impact of successful antiviral treatment
Celsa C, Cabibbo G, Fulgenzi C, Battaglia S, Enea M, Scheiner B, et al.
Hepatology . 2024 Jul; 81(3):837-852. PMID: 39028886
Background And Aims: Unlike other malignancies, hepatic functional reserve competes with tumor progression in determining the risk of mortality from hepatocellular carcinoma (HCC). However, the relative contribution of hepatic decompensation...